Human papillomavirus vaccine trials and tribulations

Handler, Nancy S.; Handler, Marc Z.; Majewski, Sławomir; Schwartz, Robert A.

doi:10.1016/j.jaad.2015.05.041

Cited by 31 publications

(23 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Educational interventions are also necessary to boost vaccination rates due to relatively poor HPV vaccine awareness among the Chinese [60]. Furthermore, because the vaccines are a relatively new development, the safety and the side effects remain a huge concern globally and affect the public’s perceptions, and consequently the coverage, of any vaccination program [61, 62]. Especially for the newer HPV9 vaccine, more monitoring and surveillance are needed to establish safety and to maintain efficacy and cross-protection against oncogenic HPV types.…”

Section: Discussionmentioning

confidence: 99%

Cost-effectiveness analysis of different types of human papillomavirus vaccination combined with a cervical cancer screening program in mainland China

Tobe

Wang

et al. 2017

BMC Infect Dis

View full text Add to dashboard Cite

Background: China has a high prevalence of human papillomavirus (HPV) and a consequently high burden of disease with respect to cervical cancer. The HPV vaccine has proved to be effective in preventing cervical cancer and is now a part of routine immunization programs worldwide. It has also proved to be cost effective. This study aimed to assess the cost-effectiveness of 2-, 4-, and 9-valent HPV vaccines (hereafter, HPV2, 4 or 9) combined with current screening strategies in China.

show abstract

Section: Discussionmentioning

confidence: 99%

Cost-effectiveness analysis of different types of human papillomavirus vaccination combined with a cervical cancer screening program in mainland China

Tobe

Wang

et al. 2017

BMC Infect Dis

View full text Add to dashboard Cite

show abstract

“…The most recent HPV vaccine, the 9-valent HPV was approved in December 2014 by the Food and Drug Administration to protect against nine strains of HPV: 4 strains from the previous quadrivalent plus five additional strains also associated with cervical cancer (Lowy, 2016). These vaccines have high efficacy against HPV 16 and 18 related cervical precancerous lesions and appear promising in the effort to reduce cervical cancer (Handler, Handler, Majewski, & Schwartz, 2015;Lowy, 2016). The U.S.…”

mentioning

confidence: 99%

Factors Associated with HPV Vaccination among Cambodian American Teenagers

Lee

Kim

Kiang

et al. 2016

Public Health Nursing

View full text Add to dashboard Cite

Background Parents have general influence over their children’s health and health behavior. However, given the dearth of specific literature regarding knowledge level and social and cultural factors influencing HPV vaccination behaviors among Cambodian American (CA) parents, it is difficult to develop an effective, evidence-based public health HPV vaccination program for this particular population without further investigation. Methods CA mothers (n=130) completed a health survey through face-to-face interviews in either English or Khmer language. Results Girls vaccination rates were 29% while that of boys was 16%. Awareness and knowledge of HPV among CA mothers was very low, and many believed that their daughters, who speak English and were educated in the U.S., had more knowledge about health than they did. Logistic regression analysis showed that Cambodian American girls had significantly higher odds of vaccination when their mothers possessed a higher level of English reading ability and had greater awareness and knowledge of HPV. Conclusions The strikingly low rates of HPV vaccination among CA girls and boys underscore the need to improve vaccination outreach, education, and uptake. The findings can be used to develop targeted public health HPV vaccination programs for CAs which will reduce cervical cancer disparities.

show abstract

“…Although not all associated strains are targeted by the vaccines, a degree of cross-protection against HPV strains not specifically targeted by the available vaccines has been demonstrated with the bivalent vaccine for subtypes 31, 33, 45, and 51. 115-117 The quadrivalent vaccine has also shown cross-protection for HPV subtypes 31, 33, and 45, 116,117 however, the bivalent vaccine has shown higher cross-protective efficacy for HPV-31 and HPV-45. 117 …”

Section: V: Potential Role Of Hpv Vaccine In Ossnmentioning

confidence: 99%